Ferring launches new company, FerGene, to focus on development of nadofaragene firadenovec to treat non-muscle invasive bladder cancer.
Ferring Pharmaceuticals and Blackstone Life Sciences announced the joint investment of over $570 million USD in nadofaragene firadenovec (rAd-IFN/Syn3), an investigational novel gene therapy in late stage development for patients with high-grade, Bacillus Calmette-Guerin (BCG) unresponsive, non-muscle invasive bladder cancer (NMIBC).
FerGene, a new gene therapy company and Ferring subsidiary, has been created to potentially commercialize nadofaragene firadenovec in the US and to advance the global clinical development. FerGene's goal is to bring this promising therapy to a patient population which has seen little improvement in their standard of care over the past twenty years.
Blackstone will invest $400 million and Ferring will invest up to $170 million in FerGene. Ferring will also potentially launch and commercialize nadofaragene firadenovec outside of the US.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins